Modelling efficacy of natalizumab in patients who switch from standard interval dosing (SID) to extended interval dosing (EID)

被引：0
|
作者：
Chang, I. [1 ]
Muralidharan, K. [1 ]
Campbell, N. [1 ]
Ho, P. -R. [1 ]
机构：
[1] Biogen, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1223
引用
下载
收藏
页码：480 / 480
页数：1
相关论文
共 50 条
  • [1] NATALIZUMAB EXTENDED INTERVAL DOSING (EID) IS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK COMPARED WITH STANDARD INTERVAL DOSING (SID) IN THE TOUCH® PRESCRIBING PROGRAM
    Ryerson, Lana Zhovtis
    Foley, John
    Chang, Ih
    Kister, Ilya
    Cutter, Gary
    Metzger, Ryan
    Goldberg, Judith D.
    Li, Xiaochun
    Riddle, Evan
    Smirnakis, Karen
    Yu, Bei
    Ren, Zheng
    Hotermans, Christophe
    Ho, Pei-Ran
    Campbell, Nolan
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E29 - E29
  • [2] Extended interval dosing of natalizumab shows comparable efficacy to standard interval dosing starting from the second year of treatment
    Ruggieri, S.
    Ianniello, A.
    De Giglio, L.
    Altieri, M.
    Centonze, D.
    Cortese, A.
    Fantozzi, R.
    Galgani, S.
    Gasperini, C.
    Landi, D.
    Marfia, G. A.
    Mirabella, M.
    Nistri, R.
    Nociti, V.
    Romano, S.
    Salvetti, M.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 1009 - 1010
  • [3] Efficacy and safety of natalizumab extended interval dosing
    Zeineddine, M.
    Ayyoubi, N.
    Tamim, H.
    Nicolas, J.
    Khoury, S.
    Yamout, B.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 871 - 871
  • [4] Extended interval dosing of natalizumab: is efficacy preserved?
    Clerico, M.
    Signori, A.
    De Mercanti, S.
    Cordioli, C.
    Signoriello, E.
    Lus, G.
    Maniscalco, G. T.
    Curti, E.
    Lorefice, L.
    Cocco, E.
    Nociti, V.
    Mirabella, M.
    Baroncini, D.
    Landi, D.
    Mataluni, G.
    Petruzzo, M.
    Lanzillo, R.
    Gandoglia, I.
    Laroni, A.
    Frangiamore, R.
    Sartori, A.
    Cavalla, P.
    Costantini, G.
    Sormani, M. P.
    Capra, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 282 - 283
  • [5] Efficacy and safety of natalizumab extended interval dosing
    Zeineddine, Maya
    Ayyoubi, Nabil
    Tamim, Hani
    Nicolas, Johny
    Khoury, Samia
    Yamout, Bassem
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP22 - NP23
  • [6] Efficacy and safety of natalizumab extended interval dosing
    Yamout, Bassem, I
    Sahraian, Mohamad Ali
    El Ayoubi, Nabil
    Tamim, Hani
    Nicolas, Johnny
    Khoury, Samia J.
    Zeineddine, Maya M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 24 : 113 - 116
  • [7] A systematic review and meta-analysis of extended interval dosing (EID) vs. standardinterval dosing (SID) of Natalizumab for multiple sclerosis patients
    Rabea, Eslam Mohammed
    Belal, Mohamed Mohamed
    Nourelden, Anas Zakarya
    Elbanna, Ashraf Hassan
    Khalifa, Mahmoud Ahmed
    Mahmoud, Nada H.
    Zaazouee, Mohamed Sayed
    NEUROLOGY, 2023, 100 (17)
  • [8] Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing
    Chang, Ih
    Muralidharan, Kumar Kandadi
    Campbell, Nolan
    Ho, Pei-Ran
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (03): : 339 - 348
  • [9] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS
    Ryerson, Lana Zhovtis
    Naismith, Robert T.
    Krupp, Lauren B.
    Charvet, Leigh
    Liao, Shirley
    Fisher, Elizabeth
    De Moor, Carl
    Williams, James R.
    Licata, Stephanie
    Campbell, Nolan
    NEUROLOGY, 2021, 96 (15)
  • [10] No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in ms paths
    Zhovtis-Ryerson, L.
    Naismith, R. T.
    Krupp, L.
    Charvet, L.
    Su, R.
    Fisher, E.
    De Moor, C.
    Williams, J.
    Campbell, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 293 - 293
12345